Replies to post #73 on Precision BioSciences Inc (DTIL)

[MI Dendream]

Thanks for posting, JonDoe. Although this looks like an exciting potential enhancement, it seems pretty far off at this point. My guess is that there is still animal work to be done before trying tuis in humans. Do you gave any idea of the stage in development at thus point?

It is quite exciting to see how engineering can be employed with the ability to genetically modify in or out. Add these kinds of improvements to the stealth advancements and sprinkle in multiple antigens and CAR-Ts are here to stsy. You know I love the dendritic cell vaccine technology, but the two don’t have to be mutually exclusive. Cancer treatments are about to take a giant leap into the future and CAR-Ts have only just gotten started.

[jondoeuk]

The poster is now up https://precisionbiosciences.com/wp-content/uploads/2022/07/Pires-M-Allogeneic-CAR-T-Cells-with-Deoxycytidine-Kinase-Knockdown.-SITC.-2021..pdf

Others, include knockdown of CD319 (reduces or prevents fratricide of CAR+ cells), TGFRB2 (less susceptible to immunosuppression by transforming growth factor beta), CBL-B (less susceptible to suppression of TCR and PD-L1 signaling), CD52 (less susceptible to CD52 antibody induced death) and/or the glucocorticoid receptor (less susceptible to glucocorticoids).

Hopefully, they will start to incorporate these and build a 'library' of additional shRNAs targeting more genes, such as PD-1 https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(21)00498-6 https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7522 https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.e14514